Journalartikel

Jahr der Veröffentlichung: 2013

Seiten: 139-143

Zeitschrift: Zeitschrift für Geburtshilfe & Neonatologie

Bandnummer: 217

Heftnummer: 4

ISSN: 0948-2393

eISSN: 1439-1651

DOI Link: https://doi.org/10.1055/s-0033-1349888

Verlag: Georg Thieme Verlag

Abstract: 
Neonatal mysthenia gravis (NMG) is a rare cause of arthrogryposis multiplex congenita (AMC) due to diaplacental transfer of maternal acetylcholine receptors (AChR) antibodies. 2 cases of severe NMG complicated by chronic lung disease and pulmonary arterial hypertension are reported. With respect to the severe course of the index patient, prenatal diagnosis and immunomodulation treatment were offered during the 2(nd) pregnancy. The combination of prenatal immunoadsorption (IA) therapy, administration of intravenous immunoglobulin (IVIG) and prednisolone failed. Failure may be partly explained by immaturity of the infant. However, considering the successful treatment of fetal/neonatal alloimmune thrombocytopenia (AIT) reported in literature, a treatment approach with IVIG doses up to 1-2g/kg per week plus prednisone/prednisolone at a higher dose up to 1mg/kg/d might be more effective.

Harvard-Zitierstil: Welcker, S., Heckmann, M., Axt-Fliedner, R. and Faas, D. (2013) Prenatal Immunomodulation Treatment in Neonatal Myasthenia Gravis, Zeitschrift für Geburtshilfe & Neonatologie, 217(4), pp. 139-143. https://doi.org/10.1055/s-0033-1349888

APA-Zitierstil: Welcker, S., Heckmann, M., Axt-Fliedner, R., & Faas, D. (2013). Prenatal Immunomodulation Treatment in Neonatal Myasthenia Gravis. Zeitschrift für Geburtshilfe & Neonatologie. 217(4), 139-143. https://doi.org/10.1055/s-0033-1349888